HSK50042 dose 3

Phase 2

HSK50042 dose 3 is one of 4 therapeutic programs targeting Idiopathic Pulmonary Fibrosis (IPF). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Idiopathic Pulmonary Fibrosis (IPF)Not yet recruiting

Idiopathic Pulmonary Fibrosis (IPF)Phase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Idiopathic Pulmonary Fibrosis (IPF)

#DrugCompanyPhaseTrials

Deupirfenidone

PPureTech

Phase 3

1 2

AK3280

SShanghai Ark Biopharmaceutical Co., Ltd.

Phase 3

1 3

HSK50042 dose 3

Haisco Pharmaceutical Group Co., Ltd.

Phase 2

1 4

LTI-03

RRein Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Idiopathic Pulmonary Fibrosis (IPF)

NCT07728721

Clinical

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis (IPF)1 trial

A Randomised, Double-blind, Placebo-controlled Parallel Group Phase II Clinical Study Evaluating the Efficacy and Safety of HSK50042 in Subjects With Idiopathic Pulmonary Fibrosis

Not yet recruiting· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT07728721·175 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HSK50042 dose 3. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for HSK50042 dose 3. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Haisco Pharmaceutical Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Haisco Pharmaceutical Group Co., Ltd.

HSK50042 dose 3

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis (IPF)1 trial

References

Drug Info

Quick Facts

Related News